Summary of pivotal trials for antithrombotic agents
| Study | Number of patients | Agent used | Indication | Treatment duration | Primary end point | Safety end point |
| PLATO 2009 | 18 624 | Aspirin+Ticagrelor vs Asprin+Clopidogrel | ACS with or without ST elevation | 12 months | Death/ MI/stroke 9.8% Ticagrelor 11.7% Clopidogrel P<0.001 | Major bleeding 11.6% Ticagrelor 11.2% Clopidogrel P=0.43 |
| TRITON 2007 | 13 608 (STEMI=3534)l | Aspirin+Prasugrel vs Aspirin+Clopidogrel | ACS 99% patients had PCI | 6–15 months | Death/MI/non-fatal MI and stroke 9.9%—Prasugrel 12.1% Clopidogrel P<0.001 | Major bleeding 2.4%—Prasugrel 1.8% Clopidogrel P=0.03 Life-threatening bleed 1.4%—Prasugrel 0.9% Clopidogrel |
| CURE 2001 | 12 562 | Aspirin+Clopidogrel vs Aspirin+Prasugrel | ACS without ST elevation | 3–12 months | Death/non-fatal stroke & MI 9.3% Clopidogrel 11.4% Prasugrel P<0.001 | Major bleeding 3.7% Clopidogrel 2.7% Prasugrel P<0.001 |
| CLARITY TIMI-28 2005 | 3491 Clopidogrel vs placebo | Fibrinolytic +anticoagulant+clopidogrel vs Fibrinolytic+clopidogrel+placebo | STEMI | 1 month | Composite of occlusion of infarct artery/death/MI 15% Clopidogrel 21.7% Prasugrel P<0.001 | TIMI major bleed 1.3% Clopidogrel 1.1% Prasugrel P=0.64 |
| OASIS-5 2007 | 20 078 | Fondaparinux vs Enoxaparin | ACS | 6 days | Death/MI/refractory ischaemia 5.8%—Fondaparinux 5.7%—Enoxaparin P=0.06 | Major bleeding 2.2%—Fondaparinux 4.1%—Enoxaparin P<0.001 |
| ATLANTIC | 1862 STEMI | Pretreatment ticagrelor vs in-laboratory ticagrelor | STEMI | End of PCI | >70% ST segment resolution TIMI 3 flow in infarct related artery before PCI | No difference in coprimary endpoints |
ACS, acute coronary syndrome; MI, Myocardial Infarction; PCI, percutaneous coronary intervention; STEMI, ST Elevation Myocardial Infarction.